StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
Huagongshe Open Project：[email protected]KI-Anbindung: llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.7.8
Zurück
HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
HCID 163091Erstellt: 27. Oktober 2026

trans-5-Chlor-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrol

Saphris · Asenapine Impurity 2 · HSDB8061 · Asenapine · HSDB 8061 · HSDB-8061 · (±)-Asenapine · Unii-jkz19V908o

https://huagongshe.com/de/chemical/163091

Molekülstruktur von trans-5-Chlor-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrol

Identifikatoren & physikalische Daten

CAS No.65576-45-6
SummenformelC17H16ClNO
Durchschnittliche Molmasse285,8 g/mol
Monoisotopische Masse285,0920418 g/mol
SMILESCN1C[C@@H]2c3ccccc3Oc3ccc(Cl)cc3[C@H]2C1
InChIKeyVSWBSWWIRNCQIJ-HUUCEWRRSA-N
PubChem CID163091
ChEMBLCHEMBL3187365
ChEBICHEBI:71257
EC No.265-829-4
Lokaler Nametrans-5-Chlor-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrol

Chemische & physikalische Eigenschaften

XLogP3,8
Polarare Oberfläche (TPSA)12,5
H-Brücken-Donoren0
H-Brücken-Akzeptoren2
Frei drehbare Bindungen0
Schwere Atome20
Formalladung0
Komplexität363
Color/FormWhite to off-white powder
Collision Cross Section167.6 Ų [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)]
Other Experimental PropertiesCrystals, mp 141-145 °Cuv max (ethanol): 270 nm (e 1900). Solubility at 21 °C (g/L): water 3, ethanol 30, methanol 250, acetone 125, ethyl acetate 10, dichloromethane 250, hexane <1. pH at 20 °C (0.1% solution in water): 4.56. pH at 23 °C (saturated solution 5.8 g/L): 4.43. pKa1 <3pKa2 = 7.52, pKa3 = 8.51 /Asenapine maleate/log Kow = 6.33 at 37 °C
Siedepunkt357.9±42.0 °C(Predicted)
Dichte1.231
LagerbedingungenStore at +4°C
LöslichkeitDMSO:50.0(Max Conc. mg/mL)174.97(Max Conc. mM)
AggregatzustandA solid
pKa (Säurekonstante)9.50±0.20(Predicted)
FarbeWhite to off-white

Sicherheit & Vorschriften

GHS-EinstufungWarningH302 (33.3%): Harmful if swallowed [Warning Acute toxicity, oral]H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]H335 (100%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposureRespiratory tract irritation]P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 3 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.
FDA-AnforderungenThe Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including asenapine maleate, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Asenapine maleate/
Hazard Classes and CategoriesAcute Tox. 4 (33.3%)Skin Irrit. 2 (100%)Eye Irrit. 2 (100%)STOT SE 3 (100%)
LagerbedingungenStore at 15-30 °C (59-86 °F)
EntsorgungsverfahrenSRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.
Wechselwirkungen

Anwendungen & Verwendung

Beschreibung

(±)-Asenapine is an atypical antipsychotic. It binds to dopamine D1-4, α-adrenergic, and histamine receptors (Kis = 0.42-1.45, 0.32-1.26, and 1-6.17 nM, respectively), as well as the serotonin (5-HT) receptor subtypes 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT5A, 5-HT6, and 5-HT7 (Kis = 0.03-3.98 nM). (±)-Asenapine inhibits the suppression of neuron firing induced by the 5-HT2A, dopamine D2, and α2-adrenergic receptor agonists 2,5-dimethoxy-4-iodoamphetamine (DOI), apomorphine, and clonidine , respectively, in rat brain (ED50s = 75, 40, and 85 μg/kg, respectively). In vivo, (±)-asenapine (0.05-0.2 mg/kg, s.c.) increases extracellular dopamine levels in the medial prefrontal cortex (mPFC), nucleus accumbens (NAc), and lateral striatum and suppresses the conditioned avoidance response in rats. It prevents acute and chronic phencyclidine-induced deficits in cued reversal learning in rats when administered at a dose of 0.075 mg/kg. Formulations containing asenapine have been used in the treatment of schizophrenia and bipolar I disorder.

Verwenden

Combined serotonin (5HT2) and dopamine (D2) receptor antagonist; structurally related to Mianserin. Antipsychotic

Potential pharmacologic interaction (possible disruption of body temperature regulation)use asenapine with caution in patients concurrently receiving drugs with anticholinergic activity.Potential pharmacologic interaction (additive CNS and respiratory depressant effects). Use with caution with other drugs that can produce CNS depression. Avoid use of alcohol during asenapine therapy.Potential pharmacologic interaction (additive effect on QT-interval prolongation)avoid concomitant use of other drugs known to prolong the corrected QT (QTc) interval, including class Ia antiarrhythmics (e.g., quinidine, procainamide), class III antiarrhythmics (e.g., amiodarone, sotalol), some antipsychotic agents (e.g., chlorpromazine, thioridazine, haloperidol, olanzapine, pimozide, paliperidone, quetiapine, ziprasidone), some antibiotics (e.g., gatifloxacin, moxifloxacin), and tetrabenazine.Because of its alpha1-adrenergic blocking activity and potential to cause hypotension, the manufacturer cautions that asenapine may enhance the hypotensive effects of certain antihypertensive agents and other drugs that can cause hypotension. Asenapine also has been associated with bradycardia. The manufacturer recommends that asenapine be used with caution in patients receiving other drugs that can cause hypotension or bradycardia, and that monitoring of orthostatic vital signs be considered in such patients. If hypotension develops, consider reducing the dosage of asenapine.For more Interactions (Complete) data for Asenapine (13 total), please visit the HSDB record page.
HepatotoxicityLiver test abnormalities occur in 1% to 2.5% of patients receiving asenapine, but similar rates are reported with placebo therapy (0.6% to 1.3%) and with comparator agents. The ALT elevations are usually mild, transient and often resolve even without dose modification or drug discontinuation. There has been a single case report of cholestatic serum enzyme elevations arising 3 to 4 weeks after starting asenapine, resolving within a month of stopping. Thus, asenapine may be a rare cause of mild cholestatic liver injury.Likelihood score: D (possible rare cause of clinically apparent liver injury).
UmweltverhaltenTERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 1.1X10+5(SRC), determined from a structure estimation method(2), indicates that asenapine is expected to be immobile in soil(SRC). The estimated pKa of asenapine is 9.64(3), indicating that this compound will exist almost entirely in the cation form in the environment and cations generally adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4). Volatilization from moist soil is not expected because the compound exists as a cation and cations do not volatilize. Asenapine is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 1.8X10-6 mm Hg at 25 °C(SRC), determined from a fragment constant method(6). Biodegradation data in soil were not available(SRC, 2012).AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 1.1X10+5(SRC), determined from a structure estimation method(2), indicates that asenapine is expected to adsorb to suspended solids and sediment(SRC). An estimated pKa of 9.64(3) indicates asenapine will exist almost entirely in the cation form at pH values of 5 to 9 and therefore volatilization from water surfaces is not expected to be an important fate process(SRC). According to a classification scheme(4), an estimated BCF of 650(SRC), from an estimated log Kow of 4.77(5) and a regression-derived equation(6), suggests the potential for bioconcentration in aquatic organisms is high, provided the compound is not metabolized by the organism(SRC). Biodegradation data in water were not available(SRC, 2012).ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), asenapine, which has an estimated vapor pressure of 1.8X10-6 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), will exist in both the vapor and particulate phases in the ambient atmosphere. Vapor-phase asenapine is degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals(SRC)the half-life for this reaction in air is estimated to be 1.4 hours(SRC), calculated from its rate constant of 9.2X10-11 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(3). Particulate-phase asenapine may be removed from the air by wet or dry deposition(SRC). Asenapine does not contain chromophores that absorb at wavelengths >290 nm(4) and, therefore, is not expected to be susceptible to direct photolysis by sunlight(SRC).
Soil Adsorption/MobilityUsing a structure estimation method based on molecular connectivity indices(1), the Koc of asenapine can be estimated to be 1.1X10+5(SRC). According to a classification scheme(2), this estimated Koc value suggests that asenapine is expected to be immobile in soil. The estimated pKa of asenapine is 9.64(3), indicating that this compound will exist partially in the cation form in the environment and cations generally adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4).
Human Toxicity Excerpts/CASE REPORTS/ ... Mr A, a 23-year-old white man, was administered asenapine 10 mg at bedtime in 2010 for a psychotic state characterized by auditory hallucinations and paranoid ideation. The auditory hallucinations were characterized by multiple voices calling him derogatory names. Prior to initiation of this treatment, the patient had received no medication. The patient was administered 3 subsequent doses without clinical improvement over the next 72 hours. On the third day of treatment, he became confusedhis confusion was characterized by disorientation to time and situation that was distinct from his psychotic state. His mother reported that he appeared "feverish" due to excess sweating. He went to a general hospital emergency room, where examination revealed his temperature to be 99.8 °F, with elevated blood pressure of 190/87 mm Hg, diaphoresis, elevated creatine kinase (719 IU/L), and leukocytosis characterized by a white blood cell count of 14.6 x 10 (+3)/cu mm. A tentative diagnosis of malignant neuroleptic syndrome was made. Because the patient was psychotic and trying to leave against medical advice, he was sedated with benzodiazepines to such a significant degree that intubation was required and then was admitted to the medical intensive care unit. Hydration, dantrolene, and bromocriptine were administered. His creatine kinase level returned to within normal limits within 36 hours, and he was extubated. After he was transferred to the inpatient psychiatric unit, his psychotic symptoms remained, but he was completely oriented and cooperated with the ward milieu. History revealed that his psychotic symptoms were gradual in onset, and a tentative diagnosis of schizophrenia (per DSM-IV criteria) was made. The above case fits with criteria for neuroleptic malignant syndrome and should remind all clinicians that all antipsychotics, whether first or second generation, have potential for this serious side effect. .../OTHER TOXICITY INFORMATION/ In patients with schizophrenia, asenapine (in sublingual dosages of 5, 10, 15, or 20 mg twice daily) was associated with relatively small increases in the corrected QT (QTc) interval of 2-5 msec compared with placebo in a controlled and dedicated QT studythese increases were slightly lower than those observed in patients receiving quetiapine. None of the asenapine-treated patients in this study experienced a QTc-interval prolongation of 60 msec or greater compared with baseline, nor did any patient experience a QTc interval of 500 msec or greater. During short-term clinical trials in patients receiving 5 or 10 mg of asenapine sublingually twice daily, post-baseline QT-interval prolongation exceeding 500 msec was reported at similar rates for asenapine and placebo. There were no reports of torsades de pointes or any adverse effects associated with delayed ventricular repolarization during these studies./OTHER TOXICITY INFORMATION/ Neuroleptic malignant syndrome (NMS), a potentially fatal syndrome requiring immediate discontinuance of the drug and intensive symptomatic treatment, has been reported in patients receiving antipsychotic agents, including asenapine.
Artificial Pollution SourcesAsenapine's production and administration as an antipsychotic(1) may result in its release to the environment through various waste streams(SRC).
Environmental BioconcentrationAn estimated BCF of 650 was calculated in fish for asenapine(SRC), using an estimated log Kow of 4.77(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is high(SRC), provided the compound is not metabolized by the organism(SRC).
Volatilization from Water/SoilAn estimated pKa of 9.64(2) indicates asenapine will exist almost entirely in the cation form at pH values of 5 to 9 and therefore volatilization from water surfaces is not expected to be an important fate process(SRC). Asenapine is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 1.8X10-6 mm Hg(SRC), determined from a fragment constant method(3).
Non-Human Toxicity Excerpts/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ In a lifetime carcinogenicity study in CD-1 mice asenapine was administered subcutaneously at doses up to those resulting in plasma levels (AUC) estimated to be 5 times those in humans receiving the maximum recommended human dose (MRHD) of 10 mg twice daily. The incidence of malignant lymphomas was increased in female mice, with a no-effect dose resulting in plasma levels estimated to be 1.5 times those in humans receiving the MRHD. The mouse strain used has a high and variable incidence of malignant lymphomas, and the significance of these results to humans is unknown. There were no increases in other tumor types in female mice. In male mice, there were no increases in any tumor type./LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Asenapine was not teratogenic in reproduction studies in rats and rabbits at intravenous doses up to 1.5 mg/kg in rats and 0.44 mg/kg in rabbits. These doses are 0.7 and 0.4 times, respectively, the maximum recommended human dose (MRHD) on a mg/sq m basis. Plasma levels of asenapine were measured in the rabbit study, and the area under the curve (AUC) at the highest dose tested was 2 times that in humans receiving the MRHD./LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ In a study in which rats were treated from day 6 of gestation through day 21 postpartum with intravenous doses of asenapine of 0.3, 0.9, and 1.5 mg/kg/day (0.15, 0.4, and 0.7 times the maximum recommended human dose (MRHD) on a mg/sq m basis), increases in post-implantation loss and early pup deaths were seen at all doses, and decreases in subsequent pup survival and weight gain were seen at the two higher doses. A cross-fostering study indicated that the decreases in pup survival were largely due to prenatal drug effects. Increases in post-implantation loss and decreases in pup weight and survival were also seen when pregnant rats were dosed orally with asenapine./LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Asenapine did not impair fertility in rats when tested at doses up to 11 mg/kg twice daily given orally. This dose is 10 times the maximum recommended human dose of 10 mg twice daily given sublingually on a mg/sq m basis./GENOTOXICITY/ No evidence for genotoxic potential of asenapine was found in the in vitro bacterial reverse mutation assay, the in vitro forward gene mutation assay in mouse lymphoma cells, the in vitro chromosomal aberration assays in human lymphocytes, the in vitro sister chromatid exchange assay in rabbit lymphocytes, or the in vivo micronucleus assay in rats.
Populations at Special RiskGeriatric patients with dementia-related psychosis treated with antipsychotic drugs appear to be at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks) revealed an approximate 1.6- to 1.7-fold increase in mortality among geriatric patients receiving atypical antipsychotic drugs (i.e., aripiprazole, olanzapine, quetiapine, risperidone) compared with that observed in patients receiving placebo. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5% compared with a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotics, treatment with conventional (first-generation) antipsychotics may increase mortalitythe extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients remains unclear. The manufacturer states that asenapine is not approved for the treatment of patients with dementia-related psychosis. /Antipsychotics/Clinical trial experience with asenapine in patients with schizophrenia or bipolar mania who are 65 years of age and older is insufficient to determine whether they respond differently from younger adults. In premarketing clinical studies, 1.1% of approximately 2250 asenapine-treated patients were 65 years of age and older. In geriatric patients (65-85 years of age) with psychosis, plasma asenapine concentrations were on average 30-40% higher compared with younger adults. The highest exposure for asenapine was up to twofold higher than the highest exposure observed in younger individuals. ... Because multiple factors that may increase the pharmacodynamic response to asenapine, resulting in poorer tolerance and orthostasis, could be present in geriatric patients, the manufacturer recommends that such patients be monitored carefully during therapy.Safety and effectiveness of asenapine have not been established in pediatric patients younger than 18 years of age.
Environmental Abiotic DegradationThe rate constant for the vapor-phase reaction of asenapine with photochemically-produced hydroxyl radicals has been estimated as 9.2X10-11 cu cm/molecule-sec at 25 °C(SRC) using a structure estimation method(1). This corresponds to an atmospheric half-life of about 1.4 hours at an atmospheric concentration of 5X10+5 hydroxyl radicals per cu cm(1). Asenapine is not expected to undergo hydrolysis in the environment due to the lack of functional groups that hydrolyze under environmental conditions(2). Asenapine does not contain chromophores that absorb at wavelengths >290 nm(2) and, therefore, is not expected to be susceptible to direct photolysis by sunlight(SRC).
Probable Routes of Human ExposureOccupational exposure to asenapine may occur through inhalation and dermal contact with this compound at workplaces where asenapine is produced or administered. Exposure to asenapine among the general population may be limited to those administered the drug, used in the treatment of schizophrenia. (SRC)
Gefahrstoffdaten65576-45-6(Hazardous Substances Data)